Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVir Biotechnology Inc

Vir Biotechnology Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
13.715 USD 1.50 ( 12.33%)
Last update at 2026-11-09T18:11:00Z
VOLUME
5121774
Market Cap
1766.61M

Momentum Score

…

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.00
Low
14.38
High
52 Week Price Range
4.82
Low
11.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vir Biotechnology is a clinical-stage immunology company developing antibody and antiviral therapies for serious infectious diseases, and it has pursued partnerships to support development and commercialization.
Long-term growth may be driven by its clinical-stage pipeline, platform-enabled discovery across multiple infectious-disease indications, and potential commercial opportunities, which could make the company attractive to investors seeking exposure to innovative infectious-disease therapeutics.
Principal risks include high clinical and regulatory uncertainty, reliance on partner relationships and commercial execution, variable revenue and cash burn that may require additional financing, and strong competitive and scientific challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.21
Dividend Yield
-
Revenue TTM
303.23M
Revenue Per Share
2.04
Gross Profit TTM
-180.08M
Debt / Equity
0.24
ROE
-26.08%
Net Debt
-47.20M
ROCE
-48.11%
Diluted EPS TTM
-1.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -437.77M -523.11M -628.19M 754.28M 549.80M
Minority interest 0.00M 0.00M 0.06M - -
Net income -437.99M -521.96M -615.06M 515.84M 528.58M
Selling general administrative 92.07M 119.03M 173.70M 161.76M 160.79M
Gross profit 56.85M -404.44M -486.65M 1434.15M 1021.20M
Reconciled depreciation 11.68M 14.56M 16.93M 6.78M 5.81M
Ebit -437.77M -523.47M -661.09M 833.07M 276.89M
Ebitda -426.09M -508.91M -641.64M 944.21M 282.70M
Depreciation and amortization 11.68M 14.56M 19.45M 111.14M 5.81M
Non operating income net other - - - - 129.05M
Operating income -468.02M -587.16M -684.30M 833.07M 276.89M
Other operating expenses 536.58M 661.37M 770.49M 747.40M 666.32M
Interest expense - - - 183.15M 272.91M
Tax provision 0.22M -1.15M -58.33M 238.44M 21.22M
Interest income 40.24M 71.81M 82.43M 28.09M 0.44M
Net interest income 40.24M 71.81M 82.43M 28.09M 0.44M
Income tax expense 0.22M -1.15M -13.08M 238.44M 21.22M
Total revenue 68.56M 74.20M 86.18M 1580.47M 1087.07M
Total operating expenses 524.87M 182.72M 197.66M 601.09M 600.45M
Cost of revenue 11.71M 478.64M 572.83M 146.32M 65.86M
Total other income expense net 30.25M 64.06M 56.11M -78.79M 272.91M
Net income from continuing ops -437.99M -521.96M -600.75M 515.84M 528.58M
Net income applicable to common shares - - - 515.84M 528.58M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1002.82M 1398.81M 1960.09M 2802.09M 1954.27M
Intangible assets 7.85M 8.10M 22.59M 32.76M 33.29M
Other current assets 47.62M 137.11M 40.95M 104.36M 73.00M
Total liab 237.55M 248.43M 369.85M 724.12M 522.42M
Total stockholder equity 765.28M 1150.38M 1590.24M 2077.96M 1431.85M
Deferred long term liab - - - - 22.25M
Other current liab 74.21M 94.18M 91.35M 484.95M 232.59M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1197.77M -759.78M -237.82M 377.24M -138.60M
Other liab - - - 89.26M 47.62M
Good will 16.94M 16.94M 16.94M 16.94M 16.94M
Other assets - 0.02M 0.00M 21.23M 9.78M
Cash 234.11M 222.95M 254.84M 848.63M 347.81M
Total current liabilities 92.81M 119.66M 175.41M 511.03M 341.24M
Current deferred revenue - 12.65M 64.85M 15.52M 98.21M
Net debt -47.20M -125.06M -130.30M -720.66M -214.25M
Short term debt 8.80M 7.75M 12.87M 4.14M 3.93M
Short long term debt total 186.91M 97.89M 124.54M 127.97M 133.56M
Other stockholder equity 1965.09M 1911.87M 1828.86M 1709.84M 1571.54M
Property plant equipment - - - 188.17M 130.05M
Total current assets 514.08M 1042.46M 1588.23M 2519.08M 1562.82M
Long term investments 314.57M 190.01M 105.28M 23.93M 201.39M
Net tangible assets - - - 2028.27M 1381.62M
Short term investments 228.75M 682.40M 1280.83M 1553.41M 360.33M
Net receivables 3.60M 5.10M 11.60M 26.40M 773.08M
Inventory - - - - 8.59M
Accounts payable 9.80M 5.08M 6.33M 6.42M 6.52M
Accumulated other comprehensive income -2.06M -1.72M -0.81M -9.12M -1.10M
Common stock total equity - - - - 0.01M
Retained earnings total equity - - - - -138.60M
Non currrent assets other 31.66M 18.42M 12.38M 21.23M 9.78M
Non current assets total 488.74M 356.33M 371.86M 283.01M 391.45M
Capital lease obligations 97.85M 97.89M 124.54M 123.84M 133.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 314.95M 499.37M 116.31M -1193.46M -119.00M
Change to liabilities - - - -32.50M 91.87M
Total cashflows from investing activities 310.37M 499.37M 164.73M -1193.46M -140.81M
Net borrowings - - -0.29M -0.26M -0.26M
Total cash from financing activities 3.79M 4.39M 7.38M 34.76M 100.33M
Change to operating activities - - - -72.17M -720.26M
Net income -437.99M -521.96M -615.06M 515.84M 528.58M
Change in cash -77.62M 57.40M -606.47M 504.55M -88.07M
Begin period cash flow 318.69M 261.29M 861.31M 363.42M 451.49M
End period cash flow 241.07M 318.69M 254.84M 867.97M 363.42M
Total cash from operating activities -391.78M -446.35M -778.78M 1663.25M -47.59M
Issuance of capital stock - 0.00M 0.00M 28.46M 85.21M
Depreciation 21.15M 14.56M 19.45M 6.78M 5.81M
Other cashflows from investing activities -4.58M 3.37M - - -
Change to inventory - - - - 52.81M
Change to account receivables - -6.51M -0.56M 770.04M -773.08M
Sale purchase of stock - - - 3.22M 15.38M
Other cashflows from financing activities 3.79M 4.39M -0.10M 3.34M 15.38M
Change to netincome - - - 475.27M 46.41M
Capital expenditures 4.83M 7.30M 21.57M 68.03M 21.82M
Change receivables - - - - -773.08M
Cash flows other operating - - - - -12.49M
Cash and cash equivalents changes - - - - -88.07M
Change in working capital -22.45M -84.01M -304.59M 665.37M -628.39M
Stock based compensation 49.07M 78.46M 111.32M 102.08M 83.78M
Other non cash items -1.57M 69.55M 122.48M 388.37M -52.56M
Free cash flow -396.61M -453.65M -800.36M 1595.22M -69.41M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VIR
Vir Biotechnology Inc		 1.50
12.33%		 13.71 - 4.27 5.83 1.85 4.57 0.90
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Vir Biotechnology Inc

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

1800 Owens Street, San Francisco, CA, United States, 94158

415 906 4324

https://www.vir.bio

367

Name Title Year Born
Dr. George A. Scangos Ph.D. Pres, CEO & Director 1948
Mr. Howard Horn Exec. VP, CFO & Sec. 1978
Dr. Ann M. Hanly Ph.D. Exec. VP & Chief Technology Officer 1970
Dr. Phillip Pang M.D., Ph.D. Exec. VP, Chief Medical Officer & Interim Head of Research 1975
Dr. Klaus Frueh Ph.D. Co-Founder & Scientific Advisor 1960
Dr. Lawrence Corey M.D. Co-Founder & Scientific Advisor NA
Dr. Louis J. Picker M.D. Co-Founder & Scientific Advisor NA
Ms. Johanna Friedl-Naderer Exec. VP & COO 1968
Mr. Steven J. Rice Exec. VP & Chief Admin. Officer 1960
Ms. Heather Rowe Armstrong VP of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…